MedTrace Logo

Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger

NCT03044756 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-02-07

No results posted yet for this study

Summary

Omitting the GnRH antagonist on the day of the trigger can be cost effective and more convenient to the women. We will study the impact of omitting the antagonist dose in a prospective randomized trial

Conditions

  • Pituitary Downregulation

Interventions

DRUG

Omit Citrotide 0.25 dose on the day of triggering of ovulation

Omit Citrotide 0.25 dose on the day of triggering of ovulation

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-08-30
Completion
2017-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03044756 on ClinicalTrials.gov